Fig. 1: Patient treatment history.
From: Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
a Timeline of the patient’s diagnosis and treatments, with molecular testing results shown in boxes. b CT scan demonstrates post chemotherapy (pre-erlotinib/crizotinib) with lung nodules. c The first on-treatment CT chest scan during erlotinib and crizotinib treatment demonstrate reduction or disappearance of lung nodules. d A CT chest of this patient at the radiographic nadir while on erlotinib and crizotinib with complete resolution of lung nodules. e A CT chest of this patient at the time of progression on erlotinib and crizotinib with new perihilar lung nodules.
